Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
Authors
Butts, CSocinski, M
Mitchell, Pa
Thatcher, Nick
Havel, L
Krzakowski, M
Nawrocki, S
Ciuleanu, T
Bosquée, L
Trigo, J
Spira, A
Tremblay, L
Nyman, J
Ramlau, R
Wickart-Johansson, G
Ellis, P
Gladkov, O
Pereira, J
Eberhardt, W
Helwig, C
Schröder, A
Shepherd, F
Affiliation
Cross Cancer Institute, Edmonton, AB, CanadaIssue Date
2014-01
Metadata
Show full item recordAbstract
Effective maintenance therapies after chemoradiotherapy for lung cancer are lacking. Our aim was to investigate whether the MUC1 antigen-specific cancer immunotherapy tecemotide improves survival in patients with stage III unresectable non-small-cell lung cancer when given as maintenance therapy after chemoradiation.Citation
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. 2014, 15 (1):59-68 Lancet OncolJournal
The Lancet OncologyDOI
10.1016/S1470-2045(13)70510-2PubMed ID
24331154Type
ArticleLanguage
enISSN
1474-5488ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(13)70510-2
Scopus Count
Collections
Related articles
- Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer.
- Authors: Katakami N, Hida T, Nokihara H, Imamura F, Sakai H, Atagi S, Nishio M, Kashii T, Satouchi M, Helwig C, Watanabe M, Tamura T
- Issue date: 2017 Mar
- Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
- Authors: Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C
- Issue date: 2012 Mar
- Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses.
- Authors: Mitchell P, Thatcher N, Socinski MA, Wasilewska-Tesluk E, Horwood K, Szczesna A, Martín C, Ragulin Y, Zukin M, Helwig C, Falk M, Butts C, Shepherd FA
- Issue date: 2015 Jun
- Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial.
- Authors: Zhang L, Ma S, Song X, Han B, Cheng Y, Huang C, Yang S, Liu X, Liu Y, Lu S, Wang J, Zhang S, Zhou C, Zhang X, Hayashi N, Wang M, INFORM investigators
- Issue date: 2012 May
- Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.
- Authors: Zhou Q, Chen M, Jiang O, Pan Y, Hu D, Lin Q, Wu G, Cui J, Chang J, Cheng Y, Huang C, Liu A, Yang N, Gong Y, Zhu C, Ma Z, Fang J, Chen G, Zhao J, Shi A, Lin Y, Li G, Liu Y, Wang D, Wu R, Xu X, Shi J, Liu Z, Cui N, Wang J, Wang Q, Zhang R, Yang J, Wu YL
- Issue date: 2022 Feb